Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis

Cytokine and Growth Factor Reviews

Volumn 26, Issue 1, 2015, Pages 35-45

  Avau, Anneleen ^a   Put, Karen ^a   Wouters, Carine H ^b   Matthys, Patrick ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cytokine profile; Defective cytotoxicity; Natural killer cells; Systemic inflammatory syndromes; Systemic juvenile idiopathic arthritis

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANIMAL CELL; ANIMAL MODEL; ARTHRITIS; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEVER; GENE EXPRESSION; HEPATOMEGALY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LYMPHADENOPATHY; MACROPHAGE ACTIVATION SYNDROME; MOUSE; MUCOSAL BLEEDING; NATURAL KILLER CELL; NONHUMAN; RASH; SHORT SURVEY; SPLENOMEGALY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; COMPLICATION; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, JUVENILE; CYTOKINES; HUMANS; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION SYNDROME; MICE; T-LYMPHOCYTES;

EID: 84923065252     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.05.005     Document Type: Short Survey

References (112)

1. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31(2):390-392.
2. Mellins E.D., Macaubas C., Grom A.A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011, 7(7):416-426.
3. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369(9563):767-778.
4. Grom A.A., Mellins E.D. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010, 22(5):561-566.
5. Kelly A., Ramanan A.V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007, 19(5):477-481.
6. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 2012, 63:233-246.
7. Jordan M.B., Allen C.E., Weitzman S., Filipovich A.H., McClain K.L. How I treat hemophagocytic lymphohistiocytosis. Blood 2011, 118(15):4041-4052.
8. de Jager W., Vastert S.J., Beekman J.M., Wulffraat N.M., Kuis W., Coffer P.J., et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60(9):2782-2793.
9. Grom A.A. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?. Arthritis Rheum 2004, 50(3):689-698.
10. Villanueva J., Lee S., Giannini E.H., Graham T.B., Passo M.H., Filipovich A., et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005, 7(1):R30-R37.
11. Vastert S.J., Kuis W., Grom A.A. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 2009, 23(5):655-664.
12. de Benedetti F., Schneider R. Systemic juvenile idiopathic arthritis. Textbook of Pediatric Rheumatology 2011, 236-248. Saunders, Philadelphia, PA. J.T. Cassidy, R.M. Laxer, R.E. Petty, C.B. Lindsey (Eds.).
13. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010, 6(4):232-241.
14. Arend W.P., Palmer G., Gabay C. IL-1 IL-18, and IL-33 families of cytokines. Immunol Rev 2008, 223:20-38.
15. Stock C.J., Ogilvie E.M., Samuel J.M., Fife M., Lewis C.M., Woo P. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun 2008, 9(4):349-357.
16. Lotito A.P., Campa A., Silva C.A., Kiss M.H., Mello S.B. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol 2007, 34(4):823-830.
17. Prahalad S., Martins T.B., Tebo A.E., Whiting A., Clifford B., Zeft A.S., et al. Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008, 6:8.
18. Yilmaz M., Kendirli S.G., Altintas D., Bingol G., Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001, 20(1):30-35.
19. Ogilvie E.M., Khan A., Hubank M., Kellam P., Woo P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56(6):1954-1965.
20. Barnes M.G., Grom A.A., Thompson S.D., Griffin T.A., Pavlidis P., Itert L., et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60(7):2102-2112.
21. Fall N., Barnes M., Thornton S., Luyrink L., Olson J., Ilowite N.T., et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007, 56(11):3793-3804.
22. Allantaz F., Chaussabel D., Stichweh D., Bennett L., Allman W., Mejias A., et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007, 204(9):2131-2144.
23. Rooney M., David J., Symons J., Di G.F., Varsani H., Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995, 34(5):454-460.
24. De Benedetti F., Pignatti P., Massa M., Sartirana P., Ravelli A., Martini A. Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1995, 13(6):779-784.
25. de Jager W., Hoppenreijs E.P., Wulffraat N.M., Wedderburn L.R., Kuis W., Prakken B.J. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007, 66(5):589-598.
26. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201(9):1479-1486.
27. Muller K., Herner E.B., Stagg A., Bendtzen K., Woo P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 1998, 37(5):562-569.
28. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008, 58(5):1505-1515.
29. Verbsky J.W., White A.J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004, 31(10):2071-2075.
30. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C., et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011, 70(5):747-754.
31. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367(25):2396-2406.
32. Macaubas C., Nguyen K.D., Peck A., Buckingham J., Deshpande C., Wong E., et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol 2012, 142(3):362-372.
33. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102(7):1369-1376.
34. Ogilvie E.M., Fife M.S., Thompson S.D., Twine N., Tsoras M., Moroldo M., et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003, 48(11):3202-3206.
35. Pignatti P., Vivarelli M., Meazza C., Rizzolo M.G., Martini A., De B.F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol 2001, 28(7):1670-1676.
36. de Benedetti F., Meazza C., Oliveri M., Pignatti P., Vivarelli M., Alonzi T., et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001, 142(11):4818-4826.
37. de Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G.R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34(9):1158-1163.
38. Cazzola M., Ponchio L., de Benedetti F., Ravelli A., Rosti V., Beguin Y., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87(11):4824-4830.
39. Shimizu M., Yachie A. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages. Cytokine 2012, 60(1):226-232.
40. Lepore L., Pennesi M., Saletta S., Perticarari S., Presani G., Prodan M. Study of IL-2, IL-6, TNF alpha IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994, 12(5):561-565.
41. Hinze C.H., Fall N., Thornton S., Mo J.Q., Aronow B.J., Layh-Schmitt G., et al. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther 2010, 12(3):R123.
42. de Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367(25):2385-2395.
43. Fife M.S., Gutierrez A., Ogilvie E.M., Stock C.J., Samuel J.M., Thomson W., et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res Ther 2006, 8(5):R148.
44. Moller J.C., Paul D., Ganser G., Range U., Gahr M., Kelsch R., et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol 2010, 28(6):912-918.
45. Raziuddin S., Bahabri S., al-Dalaan A., Siraj A.K., al-Sedairy S. A mixed Th1/Th2 cell cytokine response predominates in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. Clin Immunol Immunopathol 1998, 86(2):192-198.
46. Roark C.L., Simonian P.L., Fontenot A.P., Born W.K., O'Brien R.L. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol 2008, 20(3):353-357.
47. Omoyinmi E., Hamaoui R., Pesenacker A., Nistala K., Moncrieffe H., Ursu S., et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2012, 51(10):1881-1886.
48. Shimizu M., Nakagishi Y., Kasai K., Yamasaki Y., Miyoshi M., Takei S., et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012, 58(2):287-294.
49. Shimizu M., Yokoyama T., Yamada K., Kaneda H., Wada H., Wada T., et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010, 49(9):1645-1653.
50. Chen O., Shan N., Zhu X., Wang Y., Ren P., Wei D., et al. The imbalance of IL-18/IL-18BP in patients with systemic juvenile idiopathic arthritis. Acta Biochim Biophys Sin (Shanghai) 2013, 45(4):339-341.
51. Date Y., Seki N., Kamizono S., Higuchi T., Hirata T., Miyata K., et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum 1999, 42(12):2577-2582.
52. Quartier P., Taupin P., Bourdeaut F., Lemelle I., Pillet P., Bost M., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48(4):1093-1101.
53. Billiau A., Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 2009, 20(2):97-113.
54. Osugi Y., Hara J., Tagawa S., Takai K., Hosoi G., Matsuda Y., et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 1997, 89(11):4100-4103.
55. Akashi K., Hayashi S., Gondo H., Mizuno S., Harada M., Tamura K., et al. Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 1994, 87(2):243-250.
56. Jordan M.B., Hildeman D., Kappler J., Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104(3):735-743.
57. Pachlopnik S.J., Ho C.H., Chretien F., Lefebvre J.M., Pivert G., Kosco-Vilbois M., et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009, 1(2):112-124.
58. Mazodier K., Marin V., Novick D., Farnarier C., Robitail S., Schleinitz N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005, 106(10):3483-3489.
59. Billiau A.D., Roskams T., Van Damme-Lombaerts R., Matthys P., Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 2005, 105(4):1648-1651.
60. Ishikawa S., Mima T., Aoki C., Yoshio-Hoshino N., Adachi Y., Imagawa T., et al. Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann Rheum Dis 2009, 68(2):264-272.
61. Sikora K.A., Fall N., Thornton S., Grom A.A. The limited role of interferon-gamma in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness. Arthritis Rheum 2012, 64(11):3799-3808.
62. Canna S.W. Interferon-gamma: friend or foe in systemic juvenile idiopathic arthritis and adult still's disease. Arthritis Rheum 2014, 66(5):1072-1076.
63. Shimizu M., Nakagishi Y., Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013, 61(2):345-348.
64. de Benedetti F., Alonzi T., Moretta A., Lazzaro D., Costa P., Poli V., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997, 99(4):643-650.
65. Strippoli R., Carvello F., Scianaro R., Pasquale L.D., Vivarelli M., Petrini S., et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 2012, 64(5):1680-1688.
66. Kawane K., Tanaka H., Kitahara Y., Shimaoka S., Nagata S. Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci U S A 2010, 107(45):19432-19437.
67. Avau A., Mitera T., Put S., Put K., Brisse E., Filtjens J., et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-gamma. Arthritis Rheum 2014, 66(5):1340-1351.
68. Dungan L.S., Mills K.H. Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17. Cytokine 2011, 56(1):126-132.
69. Canna S.W., Wrobel J., Chu N., Kreiger P.A., Paessler M., Behrens E.M. Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum 2013, 65(7):1764-1775.
70. Behrens E.M., Canna S.W., Slade K., Rao S., Kreiger P.A., Paessler M., et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011, 121(6):2264-2277.
71. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9(5):503-510.
72. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999, 17:189-220.
73. Smyth M.J., Cretney E., Kelly J.M., Westwood J.A., Street S.E., Yagita H., et al. Activation of NK cell cytotoxicity. Mol Immunol 2005, 42(4):501-510.
74. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97(10):3146-3151.
75. Hallett W.H., Murphy W.J. Positive and negative regulation of Natural Killer cells: therapeutic implications. Semin Cancer Biol 2006, 16(5):367-382.
76. Dalton D.K., Pitts-Meek S., Keshav S., Figari I.S., Bradley A., Stewart T.A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993, 259(5102):1739-1742.
77. Takeda K., Tsutsui H., Yoshimoto T., Adachi O., Yoshida N., Kishimoto T., et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998, 8(3):383-390.
78. Orange J.S., Biron C.A. An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J Immunol 1996, 156(3):1138-1142.
79. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191(5):771-780.
80. Fehniger T.A., Shah M.H., Turner M.J., VanDeusen J.B., Whitman S.P., Cooper M.A., et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999, 162(8):4511-4520.
81. Mehrotra P.T., Donnelly R.P., Wong S., Kanegane H., Geremew A., Mostowski H.S., et al. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 1998, 160(6):2637-2644.
82. Brady J., Carotta S., Thong R.P., Chan C.J., Hayakawa Y., Smyth M.J., et al. The interactions of multiple cytokines control NK cell maturation. J Immunol 2010, 185(11):6679-6688.
83. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004, 172(4):2048-2058.
84. Hoshino T., Wiltrout R.H., Young H.A. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999, 162(9):5070-5077.
85. Grant L.R., Yao Z.J., Hedrich C.M., Wang F., Moorthy A., Wilson K., et al. Stat4-dependent T-bet-independent regulation of IL-10 in NK cells. Genes Immun 2008, 9(4):316-327.
86. Macaubas C., Nguyen K., Deshpande C., Phillips C., Peck A., Lee T., et al. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol 2010, 134(2):206-216.
87. Wouters C.H., Ceuppens J.L., Stevens E.A. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol 2002, 20(2):239-248.
88. Zhou J., Tang X., Ding Y., An Y., Zhao X. Natural killer cell activity and frequency of killer cell immunoglobulin-like receptors in children with different forms of juvenile idiopathic arthritis. Pediatr Allergy Immunol 2013, 24(7):691-696.
89. Shibatomi K., Ida H., Yamasaki S., Nakashima T., Origuchi T., Kawakami A., et al. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum 2001, 44(4):884-892.
90. Park Y.W., Kee S.J., Cho Y.N., Lee E.H., Lee H.Y., Kim E.M., et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009, 60(6):1753-1763.
91. Wong C.K., Li E.K., Ho C.Y., Lam C.W. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2000, 39(10):1078-1081.
92. Iannello A., Samarani S., Debbeche O., Ahmad R., Boulassel M.R., Tremblay C., et al. Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J Virol 2009, 83(12):5999-6010.
93. Grom A.A., Villanueva J., Lee S., Goldmuntz E.A., Passo M.H., Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003, 142(3):292-296.
94. Wulffraat N.M., Rijkers G.T., Elst E., Brooimans R., Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003, 42(2):375-379.
95. Vastert S.J., van Wijk R., D'Urbano L.E., de Vooght K.M., de Jager W., Ravelli A., et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49(3):441-449.
96. Henriques A., Teixeira L., Ines L., Carvalheiro T., Goncalves A., Martinho A., et al. NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. Clin Rheumatol 2013, 32(6):805-813.
97. Scheid C., Young R., McDermott R., Fitzsimmons L., Scarffe J.H., Stern P.L. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 1994, 38(2):119-126.
98. Maroof A., Beattie L., Zubairi S., Svensson M., Stager S., Kaye P.M. Posttranscriptional regulation of II10 gene expression allows natural killer cells to express immunoregulatory function. Immunity 2008, 29(2):295-305.
99. Perona-Wright G., Mohrs K., Szaba F.M., Kummer L.W., Madan R., Karp C.L., et al. Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe 2009, 6(6):503-512.
100. Sawhney S., Woo P., Murray K.J. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001, 85(5):421-426.
101. Behrens E.M., Beukelman T., Gallo L., Spangler J., Rosenkranz M., Arkachaisri T., et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008, 35(2):343-348.
102. Ravelli A., Grom A.A., Behrens E.M., Cron R.Q. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012, 13(4):289-298.
103. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002, 14(5):548-552.
104. Lehmberg K., Pink I., Eulenburg C., Beutel K., Maul-Pavicic A., Janka G. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 2013, 162(6):1245-1251.
105. Henter J.I., Horne A., Arico M., Egeler R.M., Filipovich A.H., Imashuku S., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48(2):124-131.
106. Gholam C., Grigoriadou S., Gilmour K.C., Gaspar H.B. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol 2011, 163(3):271-283.
107. Filipovich A.H. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program 2009, 2009(1):127-131.
108. Henter J.I., Tondini C., Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol 2004, 50(2):157-174.
109. Janka G.E. Hemophagocytic syndromes. Blood Rev 2007, 21(5):245-253.
110. Weitzman S. Approach to hemophagocytic syndromes. Hematology Am Soc Hematol Educ Program 2011, 2011(1):178-183.
111. Henter J.I., Elinder G., Soder O., Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991, 80(4):428-435.
112. De Benedetti F., Massa M., Pignatti P., Kelley M., Faltynek C.R., Martini A. Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J Rheumatol 1995, 22(8):1581-1585.